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Background: Treatment of prostate cancer with androgen deprivation therapy (ADT) is associated with metabolic changes that
have been linked to an increase in cardiovascular risk.
Methods: This randomised controlled trial investigated the effects of a 12-week lifestyle intervention that included supervised
exercise training and dietary advice on markers of cardiovascular risk in 50 men on long-term ADT recruited to an on-going study
investigating the effects of such a lifestyle intervention on quality of life. Participants were randomly allocated to receive the
intervention or usual care. Cardiovascular outcomes included endothelial function (flow-mediated dilatation (FMD) of the brachial
artery), blood pressure, body composition and serum lipids. Additional outcomes included treadmill walk time and exercise and
dietary behaviours. Outcomes were assessed before randomisation (baseline), and 6, 12 and 24 weeks after randomisation.
Results: At 12 weeks, the difference in mean relative FMD was 2.2% (95% confidence interval (CI) 0.1–4.3, P¼ 0.04) with an effect
size of 0.60 (95% CIo0.01–1.18) favouring the intervention group. Improvements in skeletal muscle mass, treadmill walk time and
exercise behaviour also occurred in the intervention group over that duration (Po0.05). At 24 weeks, only the difference in
treadmill walk time was maintained.
Conclusions: This study demonstrates that lifestyle changes can improve endothelial function in men on long-term ADT for
prostate cancer. The implications for cardiovascular health need further investigation in larger studies over longer duration.
Treatment with androgen deprivation therapy (ADT) has estab-
lished benefits for men with locally advanced or metastatic prostate
cancer (Schubert et al, 2012), but has been associated with the
development of adverse events that can impact physical and mental
well being (Nguyen et al, 2015). Evidence of metabolic complica-
tions of ADT that lead to increased cardiovascular risk is
accumulating (Zhao et al, 2014). Increased incidences of
abdominal adiposity, insulin resistance, hyperglycaemia and
hyperlipidaemia have been reported in men on such treatment
(Nguyen et al, 2015).
An increase in cardiovascular risk factors through the develop-
ment of metabolic complications to long-term ADT has been
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supported by evidence of a reduction in flow-mediated dilatation
(FMD) of the brachial artery in men treated with long-term
ADT (Gilbert et al, 2013). Reduced FMD indicates endothelial
dysfunction (Deanfield et al, 2007), which is regarded as an
important early stage in the development of atherosclerosis
(Celermajer, 1997). Endothelial function, as measured by brachial
artery FMD, is also an established predictor of future cardiovas-
cular events (Ras et al, 2013).
The traditional approach for presenting the results of FMD has
been in the form of absolute change in arterial diameter after
release of cuff occlusion or a simple ratio of the change of arterial
diameter over the resting arterial diameter, so-called relative FMD
(Gokce et al, 2002; Edwards et al, 2004; Green et al, 2011).
Concerns have been expressed as to the appropriateness of
simple ratio standards for such physiological variables, with
allometric scaling being deemed to be both biologically and
mathematically superior (Tanner, 1949; Packard and Boardman,
1999; Curran-Everett, 2013). More recently, the validity of this
approach has been demonstrated for FMD data (Atkinson and
Batterham, 2013; Atkinson et al, 2013).
Given the established benefits of exercise and dietary changes to
cardiovascular health in other patient groups (Rippe and
Angelopoulos, 2014), we hypothesised that a supervised exercise
training and dietary advice intervention would result in a reduction
in cardiovascular risk factors in sedentary men on ADT. We tested
this hypothesis in a randomised controlled trial and report the
results herein.
MATERIALS AND METHODS
During the course of a randomised controlled trial investigating
the effects of a lifestyle intervention on quality of life in men
with prostate cancer on ADT (trial registration number
ISRCTN88605738), a protocol amendment was approved by the
Yorkshire and Humber NHS Research Ethics Committee to
commence the collection of additional measures of cardio-
vascular risk.
The patient population and intervention for the full trial have
been described in detail previously (Bourke et al, 2014). Here we
present results for the subset of men recruited after the amendment
was implemented.
Sample size. A sample size of 50 men was deemed sufficient to
detect an absolute difference in relative brachial artery FMD of
2.6%; a difference reported in exercise studies in elderly patients at
increased cardiovascular risk (Gokce et al, 2002; Edwards et al,
2004). This sample size assumed a s.d. of 3%, an alpha of 0.05, 80%
power and 10% attrition (Bourke et al, 2011).
Randomisation. Participants were randomised 1 : 1 to receive 12
weeks of supervised exercise training and dietary advice in addition
to usual care or to receive usual care alone. A randomly ordered list
of group allocation was generated at study commencement using
the nQuery Statistical Software (nQuery Advisor 6.01, nQuery
Statistical Solution, USA). Neither the researchers nor the
participants were informed of treatment allocation until comple-
tion of baseline assessments.
Intervention and usual care. Participants were prescribed three
exercise sessions per week, tapering the supervision over the
intervention (2 : 1 supervised to home based in weeks 1–6 and
1 : 2 in weeks 7–12). An experienced exercise physiologist led
supervised sessions that lastedB1 h and consisted of a mixture of
aerobic, resistance and balance exercises. Aerobic exercise was
30min at 55–75% of age-predicted maximum heart rate or 11–13
on the Borg Rating of Perceived Exertion (RPE) scale (Borg, 1982)
using stationary cycles, rowing ergometers and treadmills.
Resistance exercises were performed for two to four sets of 8–12
repetitions beginning at an intensity of 60% of one repetition
maximum and progressed through increasing volume before
weight was increased. Advice on suitable exercises to perform at
home for a minimum of 30min was provided (e.g., brisk walking,
cycling and gym exercise). Participants were instructed how to
monitor intensity using RPE.
Small-group healthy-eating seminars led by the exercise
physiologist, lasting B20min, were delivered every 2 weeks
throughout the intervention. Advice included: reduction in dietary
fat intake toB25% of total energy intake, consumption of at least
five portions of fruit and vegetables each day, increased fibre
consumption, decreased intake of refined carbohydrates and
limiting alcohol intake to 1–2 units per day.
The control participants were men randomised to usual care
who were followed up in the urology clinic as per usual clinical
protocol. No restrictions were placed on them in relation to
exercise or dietary behaviours over the period of the study.
Outcome measures. The primary outcome was brachial artery
FMD (endothelium-dependent arterial dilatation) expressed as the
percentage change in arterial diameter at 12 weeks. Secondary
outcomes include glyceryl trinitrate (GTN)-mediated brachial
artery dilatation (endothelium-independent arterial dilatation),
resting blood pressure, treadmill walk time, body mass and
composition, lipid profile, biomarkers of disease status, physical
activity and dietary behaviours. Outcome measures were assessed
at baseline, at 6 and 12 weeks of the intervention and at 24 weeks
(12 weeks after cessation of the intervention).
Vascular assessments. Ultrasound assessments of the right
brachial artery were performed while the participant rested supine.
All assessments were undertaken by one researcher (coefficient of
variation for repeated FMD measures 10.97%) using a 7-mHz
linear array transducer attached to a high-frequency ultrasound
system (Terason T3000, Teratech Corporation, Burlington, MA,
USA). Participants rested quietly for a minimum of 15min before
commencing assessments.
For FMD assessments, a pneumatic rapid inflation/deflation
cuff (Hokanson E20 cuff, D.E. Hokanson Inc, Bellevue, WA, USA)
was placed distal to the olecranon process, with arterial imaging
performed in the distal third of the upper arm. Resting
measurement of vessel diameter was performed for 1min before
cuff inflation to a pressure 50mmHg above systolic blood pressure.
Occlusion was maintained for 5 min. Recordings were restarted
30 s before cuff release and continued for a further 3min thereafter
(Black et al, 2008).
After 15min rest following FMD assessments, GTN-mediated
brachial artery dilatation was assessed. Arterial imaging was
performed for 1min before administration of a sublingual dose
(0.4mg) of GTN, and continued for a further 6min thereafter
(Corretti et al, 2002) with recording maintained throughout.
The ultrasound on-screen display was recorded at a rate of
15Hz (Camtasia Studio software, v5.0.0, TechSmith Corporation,
Okemos, MI, USA). Subsequently, analysis was undertaken using
the Brachial Analyser for Research software package (v5.6.19,
Medical Imaging Applications, Iowa, USA). All scans were
analysed in full by a researcher external to the research team
who was blinded to participant group allocation.
Raw data for arterial diameter were smoothed before determi-
nation of the magnitude of arterial dilatation using the same
method as previously described (Black et al, 2008). Arterial data are
displayed as the absolute (millimetres) and relative (percentage)
change in arterial diameter from resting arterial diameter (Drest) to
peak arterial diameter (Dpeak). For analysis, data were allome-
trically scaled (Atkinson et al, 2013). Arterial shear rate (SR) for
FMD assessments was calculated using the equation SR¼ 4V/D,
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where V is Doppler velocity and D is vessel diameter (Parker et al,
2009). Shear rate area under the curve was calculated as the sum of
arterial shear from cuff release through to Dpeak.
Anthropometry. Stature (Holtain Stadiometer, Holtain Ltd,
Pembrokeshire, UK) and body mass (Weylux Beam Balance
Scales, Weylux, UK) were assessed using standard laboratory
techniques to 0.1 cm and 0.05 kg, respectively, and body mass
index (BMI) was calculated. Body composition was assessed via
bioelectrical impedance (Inbody 720, Biospace, Seoul, South Korea).
Resting blood pressure. Resting blood pressure and heart rate
were assessed in the left arm with an automated sphygmoman-
ometer (Dinamap, Dash 2500, GE Healthcare, Waukesha, WI,
USA) while participants rested supine before FMD assessments.
Exercise tolerance. A sub-maximal walking test was performed on
a treadmill (H/P/ Cosmos Pulsar Treadmill, Traunstein, Germany)
using the BSU/Bruce protocol (Kaminsky and Whaley, 1998).
Participants were given time walking on a treadmill before the
test to allow them to become comfortable with treadmill use.
A chest-strap heart rate monitor (Polar F4, Polar Electro, Kempele,
Finland) was fitted and participants were accustomed to the 6–20
Borg scale (Borg, 1982). Heart rate and RPE were recorded at the
end of every minute of exercise. The test ended when participants
achieved an RPE of 15 (‘Hard’) or earlier if the participant
requested to stop. Treadmill tests were conducted by a researcher
external to the research team who was blinded to participant group
allocation.
Blood markers. A fasting blood sample (20ml) was drawn from
the antecubital vein using standard venepuncture techniques.
Samples were analysed in duplicate in the Department of Clinical
Chemistry at the Royal Hallamshire Hospital, Sheffield, UK, for
blood lipid profile (total cholesterol, HDL-C, LDL-C and
triglycerides), prostate-specific antigen and male sex hormones
(testosterone, SHBG). In addition, free androgen index was
calculated.
Exercise and dietary behaviour. Leisure time physical activity was
quantified using the Godin Leisure Score Index (LSI; Godin and
Shephard, 1985). A higher score indicated more activity.
The Godin LSI has been successfully used with men on ADT
(Culos-Reed et al, 2010).
Participants completed 3-day diet diaries at baseline, 12
and 24 weeks. Where possible, participants were asked to use
the same 3 days of the week for each assessment. Nutritional data
were analysed using NetWisp (version 3.0, Tinuviel Software,
Anglesey, UK).
Statistical analysis. Analyses were performed in Stata v13 on an
intention-to-treat basis including all available participants in the
groups to which they were randomised, using two-sided sig-
nificance at the 5% level. Treatment effects are presented as the
difference in adjusted means (intervention minus control) and
Hedge’s g effect sizes with 95% confidence intervals (CIs) and
P-values.
Arterial diameter data (FMD- and GTN-mediated dilatation)
were allometrically scaled and analysed as follows. The difference
between logarithmically transformed Drest and Dpeak was calculated
for each participant and time point, and then analysed using a
covariance pattern mixed model, with treatment group, time and a
treatment group-by-time interaction as fixed factors, and log Drest
as a time-varying covariate. Means for diameter change on the
logged scale for each treatment group and time point were
obtained and then back transformed by antilogging to provide
an adjusted ratio of Dpeak/Drest, subtracting a value of 1 and
multiplying by 100 to provide a Drest adjusted estimate of relative
FMD. An estimate for the s.d. was obtained by multiplying the s.e.
of the mean diameter change by the square root of the sample size,
antilogging, subtracting 1 and multiplying by 100. Estimates for the
difference in mean diameter change between the treatment groups
at each time point were extracted from the model with 95%
CIs and P-values. The P-values are presented unchanged in this
paper, but the point and interval estimates were transformed as
described above.
To allow comparison of the results with previous publications
using a simple ratio only, the difference in (simple ratio) relative
FMD between the trial arms at 12 weeks was extracted from a
single linear covariance pattern mixed model in which relative
FMD at each time point was nested within patients (Brown and
Prescott, 2006). Relative FMD at baseline, each time point of
follow-up, trial arm and a time-by-trial arm interaction were
included in the model. The estimates of the treatment effect at 6
and 24 weeks were extracted for secondary investigations.
Estimation was based on the method of restricted maximum
likelihood (Harville, 1977).
The following outcomes were analysed in the same way as
(simple ratio) relative FMD: absolute FMD, relative GTN-mediated
dilatation, absolute GTN-mediated dilatation dilation, systolic and
diastolic blood pressure, BMI and treadmill walk time.
All other secondary outcomes were compared between the
treatment groups at 12 weeks using ANCOVA to adjust for the
baseline value. No adjustment for multiple testing was made.
RESULTS
This analysis is of 50 men (mean age 70 years—range 53–84 years)
consecutively recruited to the latter part of the primary trial
(Bourke et al, 2014) with 25 randomised to each trial arm
(Figure 1). The median time on ADT at recruitment was 19 and 18
months in the intervention and control groups, respectively. The
groups were comparable at baseline with the exception of previous
radiotherapy exposure (Table 1).
There were seven withdrawals (three in the intervention and
four in the control group) and one death (control group) before the
end of the 12-week intervention. There was one additional
withdrawal and death (both intervention group) before the
24-week assessment. Both deaths were considered unrelated to
the study intervention. For men completing the 12-week interven-
tion, adherence to supervised sessions was 93% (368 out of 396
possible) and to home-based sessions was 76% (301 out of 396
completed), respectively.
At 12 weeks, the difference in allometrically scaled relative FMD
was 2.2% (95% CI 0.1–4.3, P¼ 0.04, Hedge’s g 0.60, 95% CI
o0.01–1.18) favouring the intervention group (Table 2). The
difference in absolute FMD was 0.11mm (95% CI o0.01–0.23,
P¼ 0.05, Hedge’s g 0.59, 95% CI  0.01 to 1.17). This benefit was
not maintained at 24 weeks (0.31 s.d., 95% CI  0.27 to 0.88 for
allometrically scaled relative FMD and 0.31 s.d., 95% CI  0.27 to
0.89 for absolute FMD). The results for the non-scaled simple ratio
FMD are presented alongside the scaled results in Table 2.
There was no meaningful difference in GTN-mediated dilata-
tion (absolute or relative), systolic and diastolic blood pressure
values or BMI at any post-randomisation time point (Table 2).
Treadmill walk time improved in the intervention group. The
difference at 12 and 24 weeks was 88 s (95% CI 52–123, Po0.001,
Hedges g 1.41, 95% CI 0.76–2.05) and 69 s (95% CI 33–105,
Po0.001), respectively (Table 2).
Exercise behaviour scores from the Godin LSI were improved in
the intervention group at all follow-up time points during the
intervention with statistically significant differences at 6 and 12
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weeks (6 weeks P¼ 0.02; 12 weeks P¼ 0.05). At 12 weeks, there
was a moderate beneficial effect of the intervention of 0.57 s.d.
(95% CI  0.02 to 1.15). There was no difference detected in
exercise behaviour at 24 weeks (P¼ 0.58).
There were improvements in Dpeak for the FMD test, skeletal
muscle mass (Table 3) and SHBG (Table 4) at 12 weeks. No
meaningful change occurred in any other physiological measure or
in any dietary outcomes (Supplementary Table 1).
DISCUSSION
At the end of the exercise intervention (12 weeks), a beneficial
effect of the intervention on endothelial function occurred with an
increased relative FMD of 2.2% (effect size of 40.5 s.d.). These
differences between groups were not maintained 12 weeks after
withdrawal of the intervention (Figure 2).
There is academic debate around how best to report relative
FMD, with much of the earlier work using a simple ratio. Problems
with these ratios have been identified (Tanner, 1949) and
allometric scaling of ratio data for physiological measurements
has been shown to be a more appropriate form of data analysis and
presentation (Packard and Boardman, 1999; Curran-Everett, 2013).
Such scaling more accurately accounts for variability in body and
other anatomical sizes. Recently, Atkinson (2014) confirmed the
appropriateness of allometric scaling for changes in arterial
diameter in FMD analysis. In the current study, without such
scaling, the difference in relative FMD expressed as a simple ratio is
almost identical in magnitude (2.3%) to the allometric-scaled value
with a similar effect size (Table 2).
FMD has been widely associated with changes in cardiovascular
health. An inverse relationship between relative FMD and the risk
of future cardiovascular events (e.g., myocardial infarction and
stroke) exists, with a meta-analysis suggesting reduced cardiovas-
cular risk of 13% (95% CI 8–17%) per 1% higher relative FMD in
individuals with any pre-existing cardiovascular risk factor (Ras
et al, 2013). Although these findings have been developed from
non-scaled data, reanalysis of the Multi Ethnic Study of
Atherosclerosis indicated that allometric-scaled FMD is robust in
the association with cardiovascular health outcomes (Atkinson and
Batterham, 2013). Within the current study, 68% of the men had
pre-existing evidence of cardiovascular disease (Table 1), but a
diagnosis of prostate cancer in itself appears to be associated with
increased cardiovascular risk: a comprehensive registry-based
study from Sweden found that men diagnosed with prostate
cancer appear to constitute a particularly high-risk group for
cardiovascular events over matched controls without cancer, with
treatment by ADT conferring additional risk (Van Hemelrijck et al,
2010). An estimated annual cardiovascular event rate of B14.2%
in the Swedish PCBaSe study referred to above was reported
in a recent meta-analysis (Bosco et al, 2015). Extrapolating from
these data, one can tentatively estimate that, were the changes in
FMD seen in this study translated to clinically significant risk
reduction, 29% fewer cardiovascular events would be encoun-
tered, providing an absolute risk reduction of 4.1%. Otherwise
stated, one would have to deliver the intervention to 24 men to
prevent a single cardiovascular event per annum. As such, the
results of the current study are suggestive of cardiovascular
benefit of a 12-week exercise intervention in men on ADT,
although further studies are required to correlate changes with
cardiovascular outcomes.
Men identified as on ADT from clinic lists (n = 831)
Full details available for screening (n = 778)
Suitable to approach (n = 263)
Sent a letter (n = 183)
Expressed interest in participating (n = 44)
Approached in clinic (n = 80)
Expressed interest in participating (n = 51)
No reply (n = 69)
Not interested (n = 70)
Withdrew interest (n = 41)
Couldn’t be contacted (n = 1) Attended familiarisation (n = 53)
Consented to participate and randomised (n = 50)
Allocated to intervention (n = 25) Allocated to usual care (n = 25)
Lost to follow-up (n = 1)
Lost to follow-up (n = 2)
Died (n = 1)
Lost to follow-up (n = 1)
Followed-up at 6 weeks (n = 24)
Followed-up at 12 weeks (n = 22)
Followed-up at 24 weeks (n = 20)
Followed-up at 6 weeks (n = 21)
Followed-up at 12 weeks (n = 20)
Followed-up at 24 weeks (n = 20)
Lost to follow-up (n = 3)
Died (n = 1)
Lost to follow-up (n = 1)
Excluded:
Had health issues that had not been identified from
patient notes (n = 3)
Not interested in participating
(n = 26):
Insufficient time to participate (n = 8)
Not interested in the trial (n = 7)
Already do regular exercise (n = 6)
Other work/caring commitments (n = 5)
Travel constraints (n = 3)
Excluded at screening (n = 514):
Progressive disease (rising PSA/painful metastases) (n = 174)
comorbidities (n = 110)
Less than 6 months of ADT and/or less than 12 sience EBRT
(n = 98)
Physical impairment making participation unsuitable (n = 50)
Participating in another study (n = 35)
Active treatment for another cancer (n = 26)
Due to stop ADT in < 6 months (n = 15)
Language barrier (n = 4)
Previously stated no interest in clinical trials (n = 2)
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram for final 50 participants recruited into the main trial.
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Several mechanisms could be responsible for the changes
observed in FMD. Previous studies have demonstrated improve-
ments in endothelial function with increased physical activity are
only partly mediated by changes in traditional cardiovascular risk
factors (Green et al, 2003). A direct effect of periods of increased
shear stress on arterial walls during exercise can lead to increased
nitric-oxide-dependent vascular dilatation (Tinken et al, 2010).
Such an explanation could account for the observed changes in
FMD, despite only small effects on other cardiovascular risk
factors. Changes in SHBG at 12 weeks could be indicative of
changes in insulin resistance between groups (Wallace et al, 2013),
which could influence FMD (Suzuki et al, 2004). Although SHBG
has been shown to increase after lifestyle interventions including
exercise and diet in healthy adult males (Tymchuk et al, 1998)
consistent with changes in insulin concentrations, the results of the
current study could be interpreted as a deterioration in insulin
sensitivity in the control group leading to a reduction in SHBG
given the association between long-term ADT and increasing risk
of developing type II diabetes (Alibhai et al, 2009). However, given
the small sample size of the study, such an interpretation should be
made with caution.
Previous evidence of improvements in cardiovascular health
with exercise training in men established on ADT is limited.
Recent studies have shown improvements in anthropometric and
metabolic markers of cardiovascular risk with exercise training
(Nobes et al, 2012; Cormie et al, 2015); however, in both studies
participants started the intervention at the same time as
commencing ADT and so whether such results could be
achieved in men on long-term ADT remained unclear. Reduc-
tions in systolic and diastolic blood pressure were reported by
Culos-Reed et al (2010) in men on long-term ADT who
underwent a 16-week programme of home-based exercise;
however, changes of a similar magnitude were also found in a
non-exercising control group, resulting in no difference between
groups over time. More positively, Galvao et al (2010) reported
decreased concentrations of C-reactive protein after a 12-week
supervised exercise intervention, but this finding was not
supported by evidence of benefits in any other markers of
cardiovascular health. As such, our finding of an improvement in
endothelial function provides the most encouraging evidence of
cardiovascular benefits following a lifestyle intervention in men
on long-term ADT.
Table 1. Baseline characteristics of the participants by treatment group
Characteristic Intervention (n¼25) Control (n¼25) Total (n¼50)
Age (years) N¼25 N¼25 N¼50
Mean (s.d.) 70.1 (5.3) 70.4 (9.2) 70.2 (7.4)
(Min, max) (57, 80) (53, 84) (53, 84)
Ethnicity, n (%) N¼25 N¼25 N¼50
White 25 (100) 22 (88) 47 (94)
Asian 0 (0) 2 (8) 2 (4)
Black 0 (0) 1 (4) 1 (2)
In employment, n (%) N¼25 N¼25 N¼50
4 (16) 5 (20) 9 (18)
Smoking status, n (%) N¼25 N¼25 N¼50
Current smoker 1 (4) 0 (0) 1 (2)
Previous smoker 12 (48) 11 (44) 23 (46)
Treatment details, n (%) N¼25 N¼25 N¼50
LHRH agonist alone 25 (100) 23 (92) 48 (96)
MAB 0 (0) 2 (8) 2 (4)
Time on ADT, months N¼25 N¼25 N¼50
Median (IQR) 19 (12, 36) 18 (9, 25) 19 (9, 36)
(Min, max) (6, 138) (6, 92) (6, 138)
Previous EBRT, n (%) N¼25 N¼25 N¼50
13 (52) 7 (28) 20 (40)
Time since EBRT (months) N¼12 N¼7 N¼19
Median (IQR) 17 (12, 28) 20 (14, 58) 18 (12, 33)
(Min, max) (12, 95) (12, 130) (12, 130)
Previous radical prostatectomy, n (%) N¼25 N¼25 N¼50
1 (4) 3 (12) 4 (8)
Medical history and comorbidities, n (%) N¼25 N¼25 N¼50
Previous MI 2 (8) 2 (8) 4 (8)
Previous stroke 0 (0) 2 (8) 3 (6)
Angina 3 (12) 2 (8) 5 (10)
Diabetes 3 (12) 4 (16) 7 (14)
Hypertension 16 (64) 11 (44) 27 (54)
Hypertension diagnosed since ADT commencement 3 (12) 2 (8) 5 (10)
Medication, n (%) N¼25 N¼25 N¼50
Statin therapy 14 (56) 13 (52) 27 (54)
Beta blockers 8 (32) 6 (24) 14 (28)
Calcium channel blockers 12 (48) 4 (16) 16 (32)
ACE inhibitors 9 (36) 8 (32) 17 (34)
Diuretics 4 (16) 6 (24) 10 (20)
Angiotensin-II inhibitors 3 (12) 3 (12) 6 (12)
Prostaglandin analogues 7 (28) 6 (24) 13 (26)
Anti-coagulant therapy 2 (8) 1 (4) 3 (6)
Anti-diabetic medication 3 (12) 3 (12) 6 (12)
Abbreviations: ADT¼ androgen deprivation therapy; EBRT¼external beam radiotherapy; LHRH¼ luteinising hormone-releasing hormone; MAB¼maximum androgen blockade;
MI¼myocardial infarction.
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Statistically significant changes in skeletal muscle were observed
over the duration of the intervention. These findings support
evidence that lifestyle interventions can reverse the decrease in lean
body mass experienced by men treated with ADT (Galvao et al,
2010; Galva˜o et al, 2014). The largest effect of the intervention was
seen in treadmill walk time however. Although improvements
from baseline walking distance was seen in the control group this
did not match the magnitude of improvements in the intervention
group. This evidence demonstrates exercise training can reduce the
decline in physical function observed with ADT (Alibhai et al,
2010).
Evidence of an increase in exercise behaviour and exercise
tolerance in the control group is one limitation of the current
study. Although similar changes in exercise behaviour have
previously been reported in cancer patients randomised to a
control group of an exercise study (Courneya et al, 2004), such
findings could have a confounding effect on overall conclusions.
A further limitation of this study is that improvements in a
number of outcome measures seen at endpoint assessments in the
intervention group were lost following withdrawal of supervision.
Conducting follow-up assessments after a lifestyle intervention has
previously been undertaken by one study that reported a similar
pattern of changes (Bourke et al, 2011). Designing effective lifestyle
interventions for this population that can maintain benefits after
removal of supervision is clearly an area in which further
investigations are warranted.
Table 2. Summary of outcome measures by treatment group
Outcome
Intervention
(n¼25)
Raw mean (s.d.)
Control
(n¼25)
Raw mean
(s.d.)
Adjusted mean
difference at
12 weeks (95% CI)
P-value
Effect size in s.d.
(95% CI)
Allometrically scaled relative FMD (%)a
Baseline 4.5 (3.4) 4.6 (3.4) 2.2 (0.1, 4.3)
P¼ 0.04
0.60 (0.005, 1.18)
Week 6 6.9 (3.4) 4.4 (3.4)
Week 12 7.6 (3.4) 5.3 (3.4)
Week 24 7.5 (3.4) 6.3 (3.4)
Non-scaled relative FMD (%)a
Baseline 4.6 (4.2) 4.7 (4.2) 2.3 (0.1, 4.5)
P¼ 0.04
0.60 (0.01, 1.19)
Week 6 7.0 (3.9) 4.5 (3.8)
Week 12 7.7 (4.1) 5.3 (4.0)
Week 24 7.5 (4.0) 6.3 (4.0)
Absolute FMD (mm)
Baseline 0.23 (0.18) 0.22 (0.11) 0.11 (0.00, 0.23)
P¼ 0.05
0.59 ( 0.01, 1.17)
Week 6 0.35 (0.22) 0.23 (0.20)
Week 12 0.37 (0.20) 0.25 (0.15)
Week 24 0.37 (0.18) 0.30 (0.16)
Allometrically scaled GTN-mediated dilatation (%)a
Baseline 12.3 (4.2) 11.9 (4.2) 0.6 ( 2.4, 3.6)
P¼ 0.71
0.11 ( 0.47, 0.68)
Week 6 11.2 (4.2) 14.6 (4.2)
Week 12 11.5 (4.2) 10.9 (4.2)
Week 24 13.4 (4.2) 11.3 (4.2)
Non-scaled relative GTN-mediated dilatation (%)
Baseline 12.5 (5.0) 12.0 (4.3) 1.2 ( 2.2, 4.7)
P¼ 0.48
0.21 ( 0.37, 0.78)
Week 6 12.0 (3.5) 14.6 (6.3)
Week 12 12.2 (5.5) 10.4 (4.5)
Week 24 13.9 (4.5) 11.0 (4.9)
Absolute GTN-mediated dilatation (mm)
Baseline 0.62 (0.25) 0.59 (0.20) 0.04 ( 0.13, 0.20)
P¼ 0.66
0.13 ( 0.45, 0.70)
Week 6 0.57 (0.15) 0.74 (0.31)
Week 12 0.58 (0.27) 0.52 (0.21)
Week 24 0.67, (0.22) 0.55 (0.24)
Systolic blood pressure (mmHg)
Baseline 144 (18) 145 (20)  7.0 ( 16.1, 2.2)
P¼ 0.14
0.44 ( 0.15, 1.02)
Week 6 137 (14) 147 (19)
Week 12 138 (20) 145 (20)
Week 24 139 (19) 141 (23)
Diastolic blood pressure (mmHg)
Baseline 80 (8) 76 (8)  3.3 ( 7.0, 0.4)
P¼ 0.08
0.50 ( 0.09, 1.08)
Week 6 77 (9) 76 (7)
Week 12 76 (10) 76 (7)
Week 24 77 (11) 75 (8)
BMI (kg/m2)
Baseline 30.6 (5.0) 28.8 (5.2) 0.1 ( 0.5, 0.6)
P¼ 0.74
 0.10 ( 0.67, 0.48)
Week 6 30.3 (5.0) 28.4 (3.2)
Week 12 29.8 (4.8) 29.0 (4.8)
Week 24 28.9 (2.8) 29.0 (4.8)
Treadmill walk time (s)
Baseline 344 (144) 346 (162) 87.6 (52.0, 123.3)
Po0.001
1.41 (0.76, 2.05)
Week 6 420 (143) 411 (134)
Week 12 435 (133) 389 (115)
Week 24 447 (131) 400 (121)
Godin LSI
Baseline 20.5 (13.2) 20.7 (17.3) 12.5 ( 0.1, 25.0)
P¼ 0.05
0.57 ( 0.02, 1.15)
Week 6 31.0 (17.8) 22.4 (22.0)
Week 12 38.4 (27.2) 26.2 (21.1)
Week 24 36.5 (27.5) 31.4 (30.4)
Abbreviations: CI, confidence interval; FMD¼ Flow-mediated dilatation; GTN¼Glyceryl
trinitrate; BMI¼Body mass index; LSI¼ Leisure Score Index.
aAdjusted ‘corrected’ mean relative dilatation.
Table 3. Summary of secondary outcome measures by
treatment group
Outcome
Intervention
(n¼25)
Raw mean (s.d.)
Control
(n¼25)
Raw mean (s.d.)
Adjusted mean
difference at
12 weeks
(95% CI)
P-value
FMD Drest (mm)
Baseline 4.9 (0.6) 4.8 (0.5) 0.1 ( 0.1, 0.3)
P¼ 0.27Week 6 5.0 (0.8) 5.0 (0.6)
Week 12 5.0 (0.5) 4.8 (0.5)
Week 24 4.9 (0.6) 4.8 (0.6)
FMD Dpeak (mm)
Baseline 5.1 (0.7) 5.0 (0.6) 0.2 (0.0, 0.5)
P¼ 0.04Week 6 5.3 (0.9) 5.2 (0.7)
Week 12 5.3 (0.5) 5.1 (0.5)
Week 24 5.3 (0.6) 5.1 (0.6)
GTN Drest (mm)
Baseline 5.0 (0.5) 5.0 (0.6)  0.2 ( 0.6, 0.1)
P¼ 0.12Week 6 4.8 (0.6) 5.2 (0.6)
Week 12 4.9 (0.5) 5.2 (0.6)
Week 24 4.9 (0.4) 5.1 (0.6)
GTN Dpeak (mm)
Baseline 5.6 (0.6) 5.6 (0.7)  0.2 ( 0.6, 0.1)
P¼ 0.18Week 6 5.4 (0.6) 5.9 (0.6)
Week 12 5.5 (0.6) 5.7 (0.6)
Week 24 5.6 (0.5) 5.6 (0.6)
Body fat mass (kg)
Baseline 34.5 (11.6) 30.4 (11.5)  0.7 ( 2.2, 0.7)
P¼ 0.32Week 6 32.9 (11.2) 27.9 (7.4)
Week 12 31.6 (10.9) 29.6 (10.9)
Week 24 29.9 (7.1) 29.0 (11.1)
Skeletal muscle mass (kg)
Baseline 31.9 (4.2) 31.2 (5.7) 0.6 (0.1, 1.1)
P¼ 0.03Week 6 32.3 (4.6) 31.6 (6.0)
Week 12 32.9 (4.6) 32.3 (5.5)
Week 24 32.7 (4.0) 32.6 (5.7)
Abbreviations: CI, confidence interval; Drest¼ resting arterial diameter; Dpeak¼peak arterial
diameter; GTN¼glyceryl trinitrate; FMD¼ flow-mediated dilatation; SR AUC¼ shear rate
area under the curve.
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Finally, the controlled recruitment of men into this study could
limit generalisability of the findings. As part of the first study to
report an exercise-based intervention in men with metastatic
prostate cancer (Bourke et al, 2011, 2014), the necessity to
maintain rigour and ensure patient safety resulted in the exclusion
of 67% of men identified as being treated with ADT. Comparison
of this exclusion rate against other studies is difficult due to
variations in the detail of recruitment statistics reported; however,
the study establishes the principle that such lifestyle interventions
are feasible in this population, an important consideration for
future studies.
In conclusion, our findings demonstrate evidence of improve-
ments in endothelial function after a lifestyle intervention
including supervised exercise training and dietary advice in men
on long-term ADT for prostate cancer that were not maintained
following withdrawal of the intervention. Larger studies are
required to investigate any impact on clinically relevant cardio-
vascular outcomes, as well as the value of a longer supervised
intervention.
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